Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sally Moore

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
British Journal of Haematology|November 22, 2018
Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapseOliver C Cohen, Nicholas Counsell, Neil Rabin, et al.
British Journal of Haematology|January 22, 2022
Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T-cell responseKarthik Ramasamy, Ross Sadler, Sally Jeans, et al.
Frontiers in Oncology|December 20, 2024
A 16-week progressive exercise training intervention in treatment-naïve chronic lymphocytic leukaemia: a randomised-controlled pilot studyFrankie F Brown, Rebecca Oliver, Rachel Eddy, et al.
European Journal of Haematology|December 20, 2023
Determinants of durable humoral and T cell immunity in myeloma patients following COVID-19 vaccinationClement Twumasi, Sally Moore, Ross Sadler, et al.
Brain, Behavior, and Immunity|March 19, 2024
A single bout of vigorous intensity exercise enhances the efficacy of rituximab against human chronic lymphocytic leukaemia B-cells ex vivoHarrison D Collier-Bain, Annabelle Emery, Adam J Causer, et al.
Haematologica|January 25, 2024
Longitudinal dynamics and clinically available predictors of poor response to COVID-19 vaccination in multiple myelomaGaurav Agarwal, Sally Moore, Ross Sadler, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 18, 2015
Proof-of-Principle for Immune Control of Global HIV-1 Reactivation In VivoNicola M G Smith, Petra Mlcochova, Sarah A Watters, et al.
British Journal of Haematology|November 18, 2025
NGS-based targeted sequencing guides risk-adapted and molecularly targeted therapy decisions in multiple myelomaGaurav Agarwal, Mohammad Kazeroun, Mirian Salazar, et al.
British Journal of Haematology|June 12, 2023
Defective T-cell response to COVID-19 vaccination in acute myeloid leukaemia and myelodysplastic syndromesJustin Loke, Vinit Upasani, Charlotte Gaskell, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
British Journal of Haematology|November 22, 2018
Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapseOliver C Cohen, Nicholas Counsell, Neil Rabin, et al.
British Journal of Haematology|January 22, 2022
Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T-cell responseKarthik Ramasamy, Ross Sadler, Sally Jeans, et al.
Frontiers in Oncology|December 20, 2024
A 16-week progressive exercise training intervention in treatment-naïve chronic lymphocytic leukaemia: a randomised-controlled pilot studyFrankie F Brown, Rebecca Oliver, Rachel Eddy, et al.
European Journal of Haematology|December 20, 2023
Determinants of durable humoral and T cell immunity in myeloma patients following COVID-19 vaccinationClement Twumasi, Sally Moore, Ross Sadler, et al.
Brain, Behavior, and Immunity|March 19, 2024
A single bout of vigorous intensity exercise enhances the efficacy of rituximab against human chronic lymphocytic leukaemia B-cells ex vivoHarrison D Collier-Bain, Annabelle Emery, Adam J Causer, et al.
Haematologica|January 25, 2024
Longitudinal dynamics and clinically available predictors of poor response to COVID-19 vaccination in multiple myelomaGaurav Agarwal, Sally Moore, Ross Sadler, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 18, 2015
Proof-of-Principle for Immune Control of Global HIV-1 Reactivation In VivoNicola M G Smith, Petra Mlcochova, Sarah A Watters, et al.
British Journal of Haematology|November 18, 2025
NGS-based targeted sequencing guides risk-adapted and molecularly targeted therapy decisions in multiple myelomaGaurav Agarwal, Mohammad Kazeroun, Mirian Salazar, et al.
British Journal of Haematology|June 12, 2023
Defective T-cell response to COVID-19 vaccination in acute myeloid leukaemia and myelodysplastic syndromesJustin Loke, Vinit Upasani, Charlotte Gaskell, et al.
Pageof 7